BACKGROUND: A growing body of evidence indicates that statins decrease perioperative cardiovascular risk and that these drugs may be particularly efficacious in diabetes. Diabetes and hyperglycemia abolish the cardioprotective effects of ischemic preconditioning (IPC). The authors tested the hypothesis that simvastatin restores the beneficial effects of IPC during hyperglycemia through a nitric oxide-mediated mechanism. METHODS: Myocardial infarct size was measured in dogs (n = 76) subjected to coronary artery occlusion and reperfusion in the presence or absence of hyperglycemia (300 mg/dl) with or without IPC in separate groups. Additional dogs received simvastatin (20 mg orally daily for 3 days) in the presence or absence of IPC and hyperglycemia. Other dogs were pretreated with N-nitro-l-arginine methyl ester (30 mg intracoronary) with or without IPC, hyperglycemia, and simvastatin. RESULTS: Ischemic preconditioning significantly (P < 0.05) reduced infarct size (n = 7, 7 +/- 2%) as compared with control (n = 7, 29 +/- 3%). Hyperglycemia (n = 7), simvastatin (n = 7), N-nitro-l-arginine methyl ester alone (n = 7), and simvastatin with hyperglycemia (n = 6) did not alter infarct size. Hyperglycemia (n = 7, 24 +/- 2%), but not N-nitro-l-arginine methyl ester (n = 5, 10 +/- 1%), blocked the protective effects of IPC. Simvastatin restored the protective effects of IPC in the presence of hyperglycemia (n = 7, 14 +/- 1%), and this beneficial action was blocked by N-nitro-l-arginine methyl ester (n = 7, 29 +/- 4%). CONCLUSIONS: The results indicate that simvastatin restored the cardioprotective effects of IPC during hyperglycemia by nitric oxide-mediated signaling. The results also suggest that enhanced cardioprotective signaling could be a mechanism for statin-induced decreases in perioperative cardiovascular risk.
BACKGROUND: A growing body of evidence indicates that statins decrease perioperative cardiovascular risk and that these drugs may be particularly efficacious in diabetes. Diabetes and hyperglycemia abolish the cardioprotective effects of ischemic preconditioning (IPC). The authors tested the hypothesis that simvastatin restores the beneficial effects of IPC during hyperglycemia through a nitric oxide-mediated mechanism. METHODS:Myocardial infarct size was measured in dogs (n = 76) subjected to coronary artery occlusion and reperfusion in the presence or absence of hyperglycemia (300 mg/dl) with or without IPC in separate groups. Additional dogs received simvastatin (20 mg orally daily for 3 days) in the presence or absence of IPC and hyperglycemia. Other dogs were pretreated with N-nitro-l-arginine methyl ester (30 mg intracoronary) with or without IPC, hyperglycemia, and simvastatin. RESULTS:Ischemic preconditioning significantly (P < 0.05) reduced infarct size (n = 7, 7 +/- 2%) as compared with control (n = 7, 29 +/- 3%). Hyperglycemia (n = 7), simvastatin (n = 7), N-nitro-l-arginine methyl ester alone (n = 7), and simvastatin with hyperglycemia (n = 6) did not alter infarct size. Hyperglycemia (n = 7, 24 +/- 2%), but not N-nitro-l-arginine methyl ester (n = 5, 10 +/- 1%), blocked the protective effects of IPC. Simvastatin restored the protective effects of IPC in the presence of hyperglycemia (n = 7, 14 +/- 1%), and this beneficial action was blocked by N-nitro-l-arginine methyl ester (n = 7, 29 +/- 4%). CONCLUSIONS: The results indicate that simvastatin restored the cardioprotective effects of IPC during hyperglycemia by nitric oxide-mediated signaling. The results also suggest that enhanced cardioprotective signaling could be a mechanism for statin-induced decreases in perioperative cardiovascular risk.
Authors: Franz Kehl; John G Krolikowski; Boris Mraovic; Paul S Pagel; David C Warltier; Judy R Kersten Journal: Anesthesiology Date: 2002-01 Impact factor: 7.892
Authors: Katsuya Tanaka; Franz Kehl; Weidong Gu; John G Krolikowski; Paul S Pagel; David C Warltier; Judy R Kersten Journal: Am J Physiol Heart Circ Physiol Date: 2002-06 Impact factor: 4.733
Authors: Steven P Jones; James J M Greer; Aman K Kakkar; P Derek Ware; Richard H Turnage; Michael Hicks; Rien van Haperen; Rini de Crom; Seinosuke Kawashima; Mitsuhiro Yokoyama; David J Lefer Journal: Am J Physiol Heart Circ Physiol Date: 2003-09-11 Impact factor: 4.733
Authors: Thomas W Doebber; Linda J Kelly; Gaochao Zhou; Roger Meurer; Chhabi Biswas; Ying Li; Margaret S Wu; Marc C Ippolito; Yu-Sheng Chao; Pei-Ran Wang; Samuel D Wright; David E Moller; Joel P Berger Journal: Biochem Biophys Res Commun Date: 2004-05-28 Impact factor: 3.575
Authors: Joseph Wider; Vishnu V R Undyala; Peter Whittaker; James Woods; Xuequn Chen; Karin Przyklenk Journal: Basic Res Cardiol Date: 2018-03-09 Impact factor: 17.165
Authors: Zhi-Dong Ge; Irina A Ionova; Nikolina Vladic; Danijel Pravdic; Naoyuki Hirata; Jeannette Vásquez-Vivar; Phillip F Pratt; David C Warltier; Galen M Pieper; Judy R Kersten Journal: Cardiovasc Res Date: 2011-03-21 Impact factor: 10.787
Authors: Nikolina Vladic; Zhi-Dong Ge; Thorsten Leucker; Anna K Brzezinska; Jian-Hai Du; Yang Shi; David C Warltier; Phillip F Pratt; Judy R Kersten Journal: Am J Physiol Heart Circ Physiol Date: 2011-09-09 Impact factor: 4.733
Authors: Julien Amour; Anna K Brzezinska; Zachary Jager; Corbin Sullivan; Dorothee Weihrauch; Jianhai Du; Nikolina Vladic; Yang Shi; David C Warltier; Phillip F Pratt; Judy R Kersten Journal: Anesthesiology Date: 2010-03 Impact factor: 7.892
Authors: Julien Amour; Anna K Brzezinska; Dorothee Weihrauch; Amie R Billstrom; Jacek Zielonka; John G Krolikowski; Martin W Bienengraeber; David C Warltier; Philip F Pratt; Judy R Kersten Journal: Anesthesiology Date: 2009-02 Impact factor: 7.892